LENSAR Q3 net loss widens

LENSAR

06/11/2025 12:28

Overview

LENSAR Q3 2025 revenue rises 6% yr/yr, driven by increased procedure volume

Net loss widens to $3.7 mln in Q3, impacted by acquisition-related costs

ALLY installed base grows 77% yr/yr, reflecting strong market adoption

Outlook

Company expects Alcon acquisition to close in Q1 2026

Result Drivers

ALLY ADOPTION - Significant growth in ALLY installed base, increasing by 77% yr/yr, driving revenue growth

PROCEDURE VOLUME - Worldwide procedure volume increased by 11% in Q3 2025, contributing to revenue growth

ACQUISITION COSTS - Net loss impacted by $5.3 mln in costs related to pending Alcon acquisition

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$3.70 mln
Q3 EBITDA
-$2.70 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

Wall Street's median 12-month price target for LENSAR Inc is $15.00, about 16.5% above its November 5 closing price of $12.52

Press Release: ID:nGNX1j5kbj

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)